60 Degrees Pharmaceuticals, INC

60 Degrees Pharmaceuticals, Inc. has updated its investor presentation, highlighting its malaria prevention product ARAKODA and its pipeline for tick-borne diseases, including babesiosis.

60 Degrees Pharmaceuticals is preparing a statistical analysis plan for an interim review of its severe babesiosis trial, with potential for early reporting or sample size adjustments.

60 Degrees Pharmaceuticals, Inc. disclosed plans to seek a National Priority Review Voucher if its babesiosis trial results support an NDA submission by Q1 2028.

60 Degrees Pharmaceuticals, Inc. announced the appointment of Eric Francois to its Board of Directors, effective immediately.

60 Degrees Pharmaceuticals, Inc. filed an 8-K to correct an error in the reported beneficial ownership of an affiliate's common stock.

60 Degrees Pharmaceuticals filed an updated legal opinion confirming the validity of shares for its At-The-Market equity offering program.

60 Degrees Pharmaceuticals reported a slight decrease in product revenue for Q1 2026, alongside increased operating expenses, while continuing to focus on its infectious disease pipeline and managing its cash position.

60 Degrees Pharmaceuticals, Inc. reported increased product and research revenues for Q3 2025, but continued to incur significant net losses and raised substantial capital to address ongoing going concern doubts.

60 Degrees Pharmaceuticals reports a significantly reduced net loss and surging research revenue in Q2 2025, driven by new contracts, despite a decline in product sales and ongoing 'going concern' doubts.

60 Degrees Pharmaceuticals reports increased product and research revenues for Q1 2025, but ongoing losses raise substantial doubt about its ability to continue as a going concern.

60 Degrees Pharmaceuticals saw a significant increase in product revenue and advanced its babesiosis clinical trials during the third quarter of 2024, while also addressing past financial challenges.

60 Degrees Pharmaceuticals saw a significant increase in product revenue and advanced its babesiosis clinical trial during the second quarter of 2024, while also addressing going concern issues.

60 Degrees Pharmaceuticals details its 2024 financial results and outlines its strategic shift towards commercializing Arakoda and developing treatments for babesiosis.

60 Degrees Pharmaceuticals' annual 10-K filing outlines the company's share structure, recent financial activities, and strategic focus on infectious disease therapeutics.

Geoffrey Dow, President and CEO of 60 Degrees Pharmaceuticals, Inc., acquired 7,350 shares of common stock.

Geoffrey S. Dow, CEO of 60 Degrees Pharmaceuticals, purchased 9,670 shares of common stock, increasing his direct beneficial ownership.

Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, purchased 12,963 shares of common stock in two transactions in December 2025.

Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, acquired 7,201 shares of common stock in an open-market transaction.

60 Degrees Pharmaceuticals' COO Kristen Landon received 4,167 stock options at an exercise price of $6.85, vesting over five years.

60 Degrees Pharmaceuticals' Chief Operating Officer, Kristen Landon, acquired 4,540 shares of common stock at no cost, adjusted for a recent reverse stock split.

60 Degrees Pharmaceuticals, Inc. is calling its 2025 Annual Meeting to vote on key proposals including a potential second reverse stock split, an increase in its equity incentive plan shares, and director elections.

60 Degrees Pharmaceuticals, Inc. will hold its 2025 Annual Meeting to vote on a reverse stock split, an increase in its equity incentive plan shares, and director elections, aiming to maintain Nasdaq listing and attract talent.

60 Degrees Pharmaceuticals is holding a special meeting to seek stockholder approval for warrant exercises, an equity incentive plan amendment, and a reverse stock split to maintain its Nasdaq listing and enhance financial flexibility.

60 Degrees Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on July 16, 2024, to vote on several proposals, including director elections, an equity incentive plan amendment, a reverse stock split, and executive option modifications.

60 Degrees Pharmaceuticals, Inc. has filed an S-1 registration statement for a public offering of common stock and warrants to raise approximately $4.2 million, while its auditors have raised substantial doubt about its ability to continue as a going concern.

60 Degrees Pharmaceuticals has filed an amendment to its S-1 registration statement, covering the potential resale of up to 747,200 shares of common stock by selling stockholders, derived from the exercise of warrants.

60 Degrees Pharmaceuticals is registering for the resale of up to 3,735,977 shares of its common stock by selling stockholders, derived from warrant exercises.

60 Degrees Pharmaceuticals is seeking to raise capital through a unit offering to support its malaria prevention product and expand into new therapeutic areas like tick-borne diseases.

Knight Therapeutics Inc. has disclosed beneficial ownership of 658,629 shares, representing 19.85% of the outstanding common stock of 60 Degrees Pharmaceuticals, Inc.

CVI Investments, Inc. and Heights Capital Management, Inc. have filed a Schedule 13G, reporting beneficial ownership of 7.0% of 60 Degrees Pharmaceuticals, Inc. common stock.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, reported beneficial ownership of 263,158 shares, representing 9.1% of 60 Degrees Pharmaceuticals, Inc. common stock.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed an amended Schedule 13G, reporting a combined beneficial ownership of 4.14% in 60 DEGREES PHARMACEUTICALS, INC.

Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc. common stock.

CVI Investments and Heights Capital Management report a 9.9% beneficial ownership in 60 Degrees Pharmaceuticals, primarily through warrants.